Literature DB >> 8518636

Clozapine: progress in treating refractory schizophrenia.

S R Hirsch, B K Puri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8518636      PMCID： PMC1677898          DOI： 10.1136/bmj.306.6890.1427

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

1.  Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.

Authors:  H Y Meltzer; S Burnett; B Bastani; L F Ramirez
Journal:  Hosp Community Psychiatry       Date:  1990-08

Review 2.  Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile.

Authors:  H Y Meltzer; G A Gudelsky
Journal:  Arzneimittelforschung       Date:  1992-02

3.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 4.  Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.

Authors:  A Fitton; R C Heel
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

5.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Authors:  D Pickar; R R Owen; R E Litman; E Konicki; R Gutierrez; M H Rapaport
Journal:  Arch Gen Psychiatry       Date:  1992-05

6.  The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years.

Authors:  L H Lindström
Journal:  Acta Psychiatr Scand       Date:  1988-05       Impact factor: 6.392

7.  Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom.

Authors:  L M Davies; M F Drummond
Journal:  Br J Psychiatry       Date:  1993-01       Impact factor: 9.319

Review 8.  Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia.

Authors:  H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530
  8 in total
  10 in total

1.  Is clozapine worth its cost?

Authors:  F R Frankenburg
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

2.  Clozapine in the management of schizophrenia. Risperidone is less toxic but equally effective.

Authors:  D B Menkes
Journal:  BMJ       Date:  1993-07-17

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

4.  Clozapine in the management of schizophrenia. Clozapine has unique pharmacological profile.

Authors:  S M Dursun; M A Reveley
Journal:  BMJ       Date:  1993-07-17

5.  Clozapine in the management of schizophrenia. Compliance no worse than with other neuroleptic drugs.

Authors:  J D Wilson
Journal:  BMJ       Date:  1993-07-17

Review 6.  Community care of patients with schizophrenia: the role of the primary health care team.

Authors:  M King; I Nazareth
Journal:  Br J Gen Pract       Date:  1996-04       Impact factor: 5.386

7.  Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Authors:  G Ginsberg; S Shani; B Lev
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

8.  The short form 36 health status questionnaire: clues from the Oxford region's normative data about its usefulness in measuring health gain in population surveys.

Authors:  S Ziebland
Journal:  J Epidemiol Community Health       Date:  1995-02       Impact factor: 3.710

9.  Clozapine in the management of schizophrenia. All schizophrenic patients would benefit.

Authors:  R Kerwin; F Lofts
Journal:  BMJ       Date:  1993-07-17

Review 10.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.